Effectiveness and safety of continuous administration of tolvaptan in the treatment of refractory congestive heart failure in a multicenter cohort study

Effectiveness and safety of continuous administration of tolvaptan in the treatment of refractory congestive heart failure in a multicenter cohort study - Continuous administration of tolvaptan in the treatment of refractory congestive heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010872

Enrollment

100

Registered

2013-06-12

Start date

2013-06-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory congestive heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with heart failure They receive tolvaptan when they dischage. They take loop diuretics, thiazide, and/or aldosterone antagonist

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Functional heart failure status	—

Secondary

Measure	Time frame
1) change in body weight 2) change in congestion (edema, rales) 3) Blood test (CBC, serum Na, serum K, Uric acid, BUN, Cre) 4) serum osmolality 5) plasma BNP concentration 6) urinary osmolality 7) change in UCG findings 8) change in ECG findings	—

Countries

Japan

Contacts

Public ContactShinichi Hirotani

Hyogo College of Medicine Cardiovascular Medicine

hirotani@hyo-med.ac.jp81-798-45-6553

Outcome results